Synapse - Alexander Lesokhin

Results (381)

The checkpoint inhibitor TTI-621 (SIRPαFc) stimulates innate and adaptive immune responses in patients with hematologic and solid tumor malignancies

Meeting Abstract

Johnson, L.; Ansell, S.; Chen, R.; Flinn, I.; Maris, M.; O'Connor, O.; Lesokhin, A.; Thompson, J.; Akilov, O.; Querfeld, C.; more...
Journal for ImmunoTherapy of Cancer (2017)

Fulltext@MSK | Save

Costs and in-hospital mortality rates in autologous stem cell transplant for multiple myeloma: An analysis of the Nationwide Inpatient Sample (NIS) Database

Meeting Abstract

Liu, Y.; Han, H.; Wei, X.; Wang, Q.; He, J.; Shah, G. L.; Giralt, S. A.; Landgren, O.; Lesokhin, A.
Blood (2017)

Fulltext@MSK | Save

MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone

Meeting Abstract

Korde, N.; Mailankody, S.; Smith, E. L.; Lendvai, N.; Hassoun, H.; Lesokhin, A.; Hultcrantz, M.; Chung, D. J.; Shah, G. L.; Koehne, G.; more...
Blood (2017)

Fulltext@MSK | Save

TTI-621 (SIRPαFc), an immune checkpoint inhibitor blocking the CD47 "do not eat" signal, induces objective responses in patients with advanced, relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

Meeting Abstract

Ansell, S. M.; Flinn, I. W.; Maris, M. B.; O'Connor, O. A.; Lesokhin, A.; Advani, A. S.; Minden, M. D.; Percival, M. B. M.; Johnson, L. D. S.; Catalano, T.; more...
Blood (2017)

Fulltext@MSK | Save

Galinpepimut-S, a WT1-targeting immuno-oncology treatment, induces specific, robust and durable immune responses (IRs) in patients (Pts) with high-risk (HR) multiple myeloma (MM)